Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Tax ProvisionsTax Rate
Others
Ratios

Lexaria Bioscience (LEXX) Net Income towards Common Stockholders (2017 - 2025)

Historic Net Income towards Common Stockholders for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to $1.6 million.

  • Lexaria Bioscience's Net Income towards Common Stockholders fell 4074.07% to $1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was $10.8 million, marking a year-over-year increase of 4794.52%. This contributed to the annual value of $11.9 million for FY2025, which is 10517.24% up from last year.
  • As of Q4 2025, Lexaria Bioscience's Net Income towards Common Stockholders stood at $1.6 million, which was down 4074.07% from $2.7 million recorded in Q3 2025.
  • Over the past 5 years, Lexaria Bioscience's Net Income towards Common Stockholders peaked at $3.8 million during Q2 2025, and registered a low of -$2.6 million during Q2 2021.
  • Over the past 5 years, Lexaria Bioscience's median Net Income towards Common Stockholders value was $1.4 million (recorded in 2022), while the average stood at $1.0 million.
  • Per our database at Business Quant, Lexaria Bioscience's Net Income towards Common Stockholders crashed by 18636.16% in 2021 and then skyrocketed by 45281.79% in 2022.
  • Lexaria Bioscience's Net Income towards Common Stockholders (Quarter) stood at -$2.0 million in 2021, then soared by 190.31% to $1.8 million in 2022, then crashed by 33.33% to $1.2 million in 2023, then soared by 125.0% to $2.7 million in 2024, then plummeted by 40.74% to $1.6 million in 2025.
  • Its Net Income towards Common Stockholders was $1.6 million in Q4 2025, compared to $2.7 million in Q3 2025 and $3.8 million in Q2 2025.